Research programme: serotonin receptor-targeted therapeutics - Neurolixis

Drug Profile

Research programme: serotonin receptor-targeted therapeutics - Neurolixis

Alternative Names: Befiradol - Neurolixis; F-13640 - Neurolixis; F-15599 - Neurolixis

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis
  • Class Non-opioid analgesics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Drug-induced dyskinesia; Rett syndrome

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Rett syndrome in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA
  • 06 Mar 2014 Research programme: serotonin receptor-targeted therapeutics - Neurolixis receives Orphan Drug status for Rett syndrome in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top